Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma (Nasdaq: CBIO) granted stock options as equity inducement awards to two non-executive employees under its 2025 Employment Inducement Incentive Award Plan.

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) granted stock options as equity inducement awards to two non-executive employees under its 2025 Employment Inducement Incentive Award Plan.

The awards cover 23,550 shares total, have a 10-year term, a $17.57 exercise price, and time-based vesting tied to continued service.

Argus Jun 12 session

-2.29% close to close Open Argus

Details

News Market Reaction – CBIO

In the Jun 12 session, CBIO declined 2.29%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine hiring-related equity grants: options on 23,550 shares with a 10-y...

Analysis

This announcement details routine hiring-related equity grants: options on 23,550 shares with a 10-year term and a $17.57 exercise price, vesting over four years. It adds modest, structured dilution tied to employee retention rather than financing. In context of prior inducement awards and recent clinical and investor-relations updates, key items to watch remain trial progress, future financing actions, and how compensation levels track against pipeline milestones and cash of $189.2 million.

Key Figures

Current share price: $17.57 Inducement option size: 23,550 shares Option term: 10 years +5 more

Current share price

$17.57

Closing price used as option exercise price on June 10, 2026

Inducement option size

23,550 shares

Aggregate options granted to two non-executive employees

Option term

10 years

Life of the inducement stock options

Initial vesting

25% at 1 year

One-fourth of shares vest on first anniversary of start date

Ongoing vesting

1/48 monthly

Remaining shares vest monthly thereafter, subject to service

Cash & equivalents

$189.2 million

Balance as of March 31, 2026 from recent 8-K

Net loss

$23.3 million

Q1 2026 net loss, or $0.70 per share

Q1 2026 revenue

$1.0 million

Reported in April 29, 2026 8-K

Historical Context

5 past events · Latest: Jun 02

5 events

1. Jun 02

   Investor conferences

   24h Move

   +5.7%

   Announced fireside chats at two June 2026 investor conferences.

2. May 29

   Inducement awards

   24h Move

   -4.5%

   Granted inducement options on 16,950 shares with four-year vesting.

3. May 21

   Clinical trial update

   24h Move

   +2.5%

   Detailed ASCEND Phase 1/2 CR-001 trial-in-progress ASCO poster.

4. May 12

   Inducement awards

   24h Move

   +6.2%

   Granted options on 129,075 shares as equity inducement awards.

5. May 06

   Investor conferences

   24h Move

   -0.1%

   Announced management presentations at three May 2026 conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

equity inducement awards, exercise price, Nasdaq Listing Rule 5635(c)(4)

3 terms

equity inducement awards financial

"to two non-executive employees as equity inducement awards under the Crescent"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

exercise price financial

"a 10-year term and an exercise price equal to $17.57, the closing price per"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Nasdaq Listing Rule 5635(c)(4) regulatory

"with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4). The options"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 23,550 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on June 10, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $17.57, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on June 10, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma 

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. 

Contacts

Investors

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media

Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement awards did Crescent Biopharma (CBIO) grant on June 10, 2026?

Crescent Biopharma granted stock options to purchase an aggregate 23,550 ordinary shares as equity inducement awards to two non-executive employees. According to the company, these options were approved under its 2025 Employment Inducement Incentive Award Plan, as amended, to support new hires.

What is the exercise price and term of the new Crescent Biopharma (CBIO) inducement options?

The inducement options have an exercise price of $17.57 per share and a 10-year term. According to Crescent, the exercise price equals the June 10, 2026 Nasdaq closing price for its ordinary shares, aligning the awards with the market value at grant.

How do the Crescent Biopharma (CBIO) inducement stock options vest for new employees?

The options vest 25% on the first anniversary of each employee’s start date, then 1/48 monthly thereafter. According to Crescent, vesting is subject to continuous service through the applicable vesting dates, encouraging longer-term employee retention and alignment with shareholders.

Why were Crescent Biopharma (CBIO) inducement awards important for the new employees?

The company states the options were material to each employee’s acceptance of employment with Crescent. According to Crescent, these equity awards support talent recruitment while complying with Nasdaq Listing Rule 5635(c)(4) for inducement grants outside shareholder-approved plans.

Under which plan were Crescent Biopharma (CBIO) inducement options granted?

The stock options were granted under the Crescent Biopharma 2025 Employment Inducement Incentive Award Plan, as amended. According to the company, the awards are also governed by individual option agreements that specify detailed terms and conditions for each grant.